June 20 – 22, 2023 | Boston, MA

With CD73 leading the way with 65 trials making progress through the clinical phases of development and CD39 close behind with 13 trials in play, the Adenosine landscape is bubbling with activity!

With all this excitement, now is the time to channel this energy into your adenosine pipelines and learn from the experience of others to help meet the needs of patients and continue to strive for a cancer-free world. The 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit is devoted to keeping the space moving while awaiting landmark results from AstraZeneca’s first-of-its-kind Phase 3 study into adenosine, by underpinning the biology of adenosine and directly linking this to improving the efficacy of drugs that target the adenosine pathway and accelerating the translation of therapeutics into the clinic.

Also, don’t miss the opportunity to hear an exclusive presentation, encompassing the current development, clinical trials, and key players in the clinical trial landscape of Adenosine-pathway targeted therapies, by Beacon’s Checkpoint team.

Be part of the revolution to develop a new generation of immuno-oncology therapeutics.